Drug intelligence / Profile preview

ANXA7-I1 lentivirus

Development stage: Preclinical
Lead developer: University of Alabama at Birmingham
Modality: Gene Therapies
Administration: Intratumoral

Overview

ANXA7-I1 lentivirus is an experimental gene therapy construct designed to overexpress the Annexin A7 isoform 1 (I1) protein, specifically for the treatment of glioblastoma (GBM). In GBM, the Epidermal Growth Factor Receptor (EGFR) often escapes degradation and is recycled to the cell surface, maintaining hyperactive signaling. ANXA7-I1 contains unique tyrosine residues that, when phosphorylated, facilitate the trafficking of EGFR to lysosomes for degradation. Research presented at the Society for Neuro-Oncology (SNO) meetings in 2024 and 2025 demonstrates that lentiviral delivery of ANXA7-I1 in glioma stem cells (GSCs) reduces total and surface EGFR levels, thereby inhibiting downstream signaling. This mechanism represents a potential therapeutic strategy to overcome RTK-driven resistance and reduce the tumorigenicity of GSC populations.

Other names: Annexin A7 isoform 1 lentivirusANXA7 isoform 1 lentivirusANXA-7 isoform 1 lentivirusANXA 7 isoform 1 lentivirus

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)PDGFRA (Platelet-derived growth factor receptor alpha)MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on ANXA7-I1 lentivirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANXA7-I1 lentivirus.

Explore the full profile